Terms ending in 2030
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,173,621 | Nucleoside Cyclicphosphates In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,716,263 | Synthesis of Purine Nucleosides In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,093,226 | Novel Cytostatic 7-Deazapurine Nucleosides In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 7,939,545 | Inhibitors of Human Immunodeficiency Virus Replication In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,012,942 | Carba-Nucleoside Analogs for Antiviral Treatment In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,551,973 | Nucleoside Analogs In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,716,262 | Nucleoside Phosphoramidates In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,173,623 | Process for Preparation of HIV Protease Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,853,210 | Methods and Intermediates for Preparing Pharmaceutical Agents In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 9,115,100 | Methods and Intermediates for Preparing Pharmaceutical Agents In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| 39 more term ends in 2030 · Pro | |||||
10 of 49 patents shown. Soonest term end first, then patent number.
Pro members see all 49.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.